SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549


                                   FORM 8-K


                                CURRENT REPORT
                      Pursuant to Section 13 or 15(d) of
                      the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported) March 1, 2002
                                                         -------------


                       Commission File Number 000-23386
                                                  -----


                         CRYO-CELL INTERNATIONAL, INC.
                         -----------------------------
                (Name of Small Business Issuer in its charter)


          DELAWARE                           22-3023093
          ----------------------------       -------------------
          (State or other jurisdiction       (I.R.S. Employer
          of incorporation or                Identification No.)
          organization)


          3165 McMullen Booth Road, Building B, Clearwater, FL  33761
          -----------------------------------------------------------
            (Address of Principal Executive Offices)     (Zip Code)


          Issuer's phone number, including area code: (727) 450-8000


             _____________________________________________________
         (Former name or former address, if changed since last report)

Item 5.  Other Events


     On February 22, 2002 the Company received a complaint filed by Pharmastem
Therapeutics, Inc. alleging patent infringement. Pharmastem, a Delaware
corporation, has named eight companies active in cord blood banking in the suit
which seeks an injunction against the companies, an unspecified amount of
damages or royalties, treble damages and attorney's fees.

     The Company has consulted with their patent attorney who believes that the
asserted patents are not valid and even if valid, believes that CRYO-CELL's
business of collecting, processing and cryopreserving cord blood cells does not
infringe either of the asserted patents. The Company  also notes that it
believes that the corresponding patents in other jurisdictions outside the
United States have been invalidated.

                                  SIGNATURES


        Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                  CRYO-CELL INTERNATIONAL, INC.


Date March 1, 2002                By: /s/ Daniel D. Richard
                                      -----------------------
                                      Daniel D. Richard
                                      Chief Executive Officer